References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA: a cancer
journal for clinicians. 2018;68(6):394-424.
2. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci
JC, et al. Head and Neck cancers-major changes in the American Joint
Committee on cancer eighth edition cancer staging manual. CA: a cancer
journal for clinicians. 2017;67(2):122-37.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer
journal for clinicians. 2018;68(1):7-30.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer
journal for clinicians. 2019;69(1):7-34.
5. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E,
et al. Human papillomavirus and rising oropharyngeal cancer incidence in
the United States. Journal of clinical oncology : official journal of
the American Society of Clinical Oncology. 2011;29(32):4294-301.
6. Santuray RT, Johnson DE, Grandis JR. New Therapies in Head and Neck
Cancer. Trends in cancer. 2018;4(5):385-96.
7. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et
al. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
The New England journal of medicine. 2008;359(11):1116-27.
8. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein
DJ, et al. Radiotherapy plus cetuximab or cisplatin in human
papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a
randomised, multicentre, non-inferiority trial. Lancet.
2019;393(10166):40-50.
9. Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From
Enhancement to Normalization. Cell. 2018;175(2):313-26.
10. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role
of pro-survival signalling in cancer. Annals of oncology : official
journal of the European Society for Medical Oncology. 2016;27(3):409-16.
11. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as
cancer therapeutics. Journal of hematology & oncology. 2019;12(1):92.
12. Galvis MM, Borges GA, Oliveira TB, Toledo IP, Castilho RM, Guerra
ENS, et al. Immunotherapy improves efficacy and safety of patients with
HPV positive and negative head and neck cancer: A systematic review and
meta-analysis. Critical reviews in oncology/hematology. 2020;150:102966.
13. Wang BC, Cao RB, Fu C, Chen WB, Li PD, Lin GH, et al. The efficacy
and safety of PD-1/PD-L1 inhibitors in patients with recurrent or
metastatic nasopharyngeal carcinoma: A systematic review and
meta-analysis. Oral Oncol. 2020;104:104640.
14. Xu Y, Zhu G, Maroun CA, Wu IXY, Huang D, Seiwert TY, et al.
Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent
or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human
Papillomavirus Status: A Systematic Review and Meta-Analysis. Frontiers
in immunology. 2021;12:645170.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement.
BMJ (Clinical research ed). 2009;339:b2535.
16. Mark Mitchell BMaTWea. ”Engauge Digitizer Software.”.http://markummitchellgithubio/engauge-digitizer.
(accessed: January 8, 2021).
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical
methods for incorporating summary time-to-event data into meta-analysis.
Trials. 2007;8:16.
18. Schünemann H BJ, Guyatt G, Oxman A, editors. GRADE handbook for
grading quality of evidence and strength of recommendations. Updated
October 2013. . The GRADE Working Group
http://guidelinedevelopmentorg/handbook2013. (accessed: February 19, 2021).
19. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et
al. GRADE guidelines: 3. Rating the quality of evidence. Journal of
clinical epidemiology. 2011;64(4):401-6.
20. University M. GRADEpro GDT: GRADEpro Guideline Development Tool
[Software]. http://gradeproorg/.
2020 (developed by Evidence Prime, Inc.).(accessed: February 19, 2021).
21. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD,
Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the
Head and Neck. The New England journal of medicine.
2016;375(19):1856-67.
22. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro
G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with
chemotherapy for recurrent or metastatic squamous cell carcinoma of the
head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet. 2019;394(10212):1915-28.
23. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ,
et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for
recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet.
2019;393(10167):156-67.
24. Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et
al. Durvalumab with or without tremelimumab in patients with recurrent
or metastatic head and neck squamous cell carcinoma: EAGLE, a
randomized, open -label phase III study. Annals of Oncology.
2020;31(7):942-50.
25. Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, et al.
Avelumab–cetuximab–radiotherapy versus standards of care in locally
advanced squamous-cell carcinoma of the head and neck: The safety phase
of a randomised phase III trial GORTEC 2017-01 (REACH). European Journal
of Cancer. 2020;141:21-9.
26. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al.
Safety and clinical activity of pembrolizumab for treatment of recurrent
or metastatic squamous cell carcinoma of the head and neck
(KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet
Oncology. 2016;17(7):956-65.
27. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, et al.
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck
Cancer: Results From a Single-Arm, Phase II Study. Journal of clinical
oncology : official journal of the American Society of Clinical
Oncology. 2017;35(14):1542-9.
28. Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG,
et al. Safety and clinical activity of atezolizumab in head and neck
cancer: results from a phase I trial. Annals of Oncology.
2018;29(11):2247-53.
29. Segal NH, Ou SHI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR,
et al. Safety and efficacy of durvalumab in patients with head and neck
squamous cell carcinoma: results from a phase I/II expansion cohort.
European Journal of Cancer. 2019;109:154-61.
30. Siu LL, Even C, Mesia R, Remenar E, Daste A, Delord JP, et al.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in
Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase
2 CONDOR Randomized Clinical Trial. Jama Oncology. 2019;5(2):195-203.
31. Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et
al. Durvalumab for recurrent or metastatic head and neck squamous cell
carcinoma: Results from a single-arm, phase II study in patients with
≥25% tumour cell PD-L1 expression who have progressed on platinum-based
chemotherapy. European journal of cancer (Oxford, England : 1990).
2019;107:142-52.
32. Elbers JBW, Al-Mamgani A, Tesseslaar MET, van den Brekel MWM, Lange
CAH, van der Wal JE, et al. Immuno-radiotherapy with cetuximab and
avelumab for advanced stage head and neck squamous cell carcinoma:
Results from a phase-I trial. Radiotherapy and Oncology. 2020;142:79-84.
33. Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, et al.
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally
Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
Journal of Clinical Oncology. 2020;38(21):2427-+.
34. Weiss J, Sheth S, Deal AM, Olson JEG, Patel S, Hackman TG, et al.
Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV
Head and Neck Cancer and Cisplatin Contraindication. Clinical Cancer
Research. 2020;26(16):4260-7.
35. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF,
et al. Human papillomavirus and survival of patients with oropharyngeal
cancer. The New England journal of medicine. 2010;363(1):24-35.
36. Chow LQM. Head and Neck Cancer. The New England journal of medicine.
2020;382(1):60-72.
37. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1,
a novel member of the immunoglobulin gene superfamily, upon programmed
cell death. The EMBO journal. 1992;11(11):3887-95.
38. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et
al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7
family member leads to negative regulation of lymphocyte activation. The
Journal of experimental medicine. 2000;192(7):1027-34.
39. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I,
et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Nature immunology. 2001;2(3):261-8.
40. Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2
Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Clinical cancer research : an official journal of the American
Association for Cancer Research. 2017;23(12):3158-67.
41. Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer.
Journal of clinical oncology : official journal of the American Society
of Clinical Oncology. 2015;33(29):3293-304.
42. Essers PBM, van der Heijden M, Verhagen CVM, Ploeg EM, de Roest RH,
Leemans CR, et al. Drug Sensitivity Prediction Models Reveal a Link
between DNA Repair Defects and Poor Prognosis in HNSCC. Cancer Res.
2019;79(21):5597-611.
43. Kobayashi K, Hisamatsu K, Suzui N, Hara A, Tomita H, Miyazaki T. A
Review of HPV-Related Head and Neck Cancer. Journal of clinical
medicine. 2018;7(9).
44. Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, et al. Immune
Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer.
Immunity. 2020;52(1):183-99.e9.
45. Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei
Y, et al. PD-1 Status in CD8(+) T Cells Associates with Survival and
Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res.
2017;77(22):6353-64.
46. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano
JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the
head and neck. The New England journal of medicine.
2007;357(25):2552-61.
47. Solomon B, Young RJ, Rischin D. Head and neck squamous cell
carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer
treatments. Semin Cancer Biol. 2018;52(Pt 2):228-40.
48. Lenouvel D, González-Moles M, Ruiz-Ávila I, Gonzalez-Ruiz L,
Gonzalez-Ruiz I, Ramos-García P. Prognostic and clinicopathological
significance of PD-L1 overexpression in oral squamous cell carcinoma: A
systematic review and comprehensive meta-analysis. Oral Oncol.
2020;106:104722.
49. Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL.
Clinical Significance of PD-L1(+) Exosomes in Plasma of Head and Neck
Cancer Patients. Clinical cancer research : an official journal of the
American Association for Cancer Research. 2018;24(4):896-905.
50. Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M,
Economopoulou P, et al. Prognostic significance of PD-L1 expression on
circulating tumor cells in patients with head and neck squamous cell
carcinoma. Annals of oncology : official journal of the European Society
for Medical Oncology. 2017;28(8):1923-33.
51. Orlov S, Salari F, Kashat L, Walfish PG. Induction of painless
thyroiditis in patients receiving programmed death 1 receptor
immunotherapy for metastatic malignancies. The Journal of clinical
endocrinology and metabolism. 2015;100(5):1738-41.
52. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy -
immune checkpoint blockade and associated endocrinopathies. Nature
reviews Endocrinology. 2017;13(4):195-207.